Correlation between metastatic site and response to anti-Programmed Death-1 (PD-1) agents in melanoma.

被引：15
|
作者：
Goldinger, Simone M.
Tsai, Katy K.
Tumeh, Paul
Hamid, Omid
Nosrati, Adi
Loo, Kimberly
Grimes, Barbara
Algazi, Alain Patrick
Levesque, Mitchell P.
Dummer, Reinhard
Daud, Adil
机构：
[1] Univ Zurich Hosp, Zurich, Switzerland
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Univ Calif Los Angeles, Los Angeles, CA USA
[4] Angeles Clin & Res Inst, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.9549
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9549
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Clinical activity of anti -programmed death-1 (PD-1) agents in acral and mucosal melanoma.
    Munhoz, Rodrigo Ramella
    Shoushtari, Alexander Noor
    Kuk, Deborah
    Ott, Patrick Alexander
    Johnson, Douglas Buckner
    Tsai, Katy K.
    Rapisuwon, Suthee
    Eroglu, Zeynep
    Sullivan, Ryan J.
    Luke, Jason John
    Gangadhar, Tara C.
    Salama, April K.
    Clark, Varina
    Burias, Clare
    Puzanov, Igor
    Atkins, Michael B.
    Algazi, Alain Patrick
    Ribas, Antoni
    Wolchok, Jedd D.
    Postow, Michael Andrew
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Anti-Programmed Cell Death-1 (PD-1) Monoclonal Antibodies in Treating Advanced Melanoma
    Metcalfe, Whitney
    Anderson, Jaime
    Van Anh Trinh
    Hwu, Wen-Jen
    [J]. DISCOVERY MEDICINE, 2015, 19 (106) : 393 - 401
  • [3] Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.
    Nie, Run-Cong
    Yuan, Shu-Qiang
    Li, Yuanfang
    Chen, Yingbo
    Zhou, Zhiwei
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients
    Valentine Heidelberger
    François Goldwasser
    Nora Kramkimel
    Anne Jouinot
    Nathalie Franck
    Jennifer Arrondeau
    Sarah Guégan
    Audrey Mansuet-Lupo
    Jérôme Alexandre
    Diane Damotte
    Marie-Françoise Avril
    Nicolas Dupin
    Sélim Aractingi
    [J]. Investigational New Drugs, 2017, 35 : 842 - 847
  • [5] Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients
    Heidelberger, Valentine
    Goldwasser, Francois
    Kramkimel, Nora
    Jouinot, Anne
    Franck, Nathalie
    Arrondeau, Jennifer
    Guegan, Sarah
    Mansuet-Lupo, Audrey
    Alexandre, Jerome
    Damotte, Diane
    Avril, Marie-Francoise
    Dupin, Nicolas
    Aractingi, Selim
    [J]. INVESTIGATIONAL NEW DRUGS, 2017, 35 (06) : 842 - 847
  • [6] When is it OK to Stop Anti-Programmed Death 1 Receptor (PD-1) Therapy in Metastatic Melanoma?
    Lauren B. Banks
    Ryan J. Sullivan
    [J]. American Journal of Clinical Dermatology, 2020, 21 : 313 - 321
  • [7] Anti-Programmed Cell Death-1 (PD-1) Monoclonal Antibodies in Treating Advanced Melanoma - A Clinical Update
    Van Anh Trinh
    Joseph, Jocelyn
    Hwu, Wen-Jen
    [J]. DISCOVERY MEDICINE, 2018, 25 (135) : 31 - 40
  • [8] When is it OK to Stop Anti-Programmed Death 1 Receptor (PD-1) Therapy in Metastatic Melanoma?
    Banks, Lauren B.
    Sullivan, Ryan J.
    [J]. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2020, 21 (03) : 313 - 321
  • [9] Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma
    Nie, Run-Cong
    Yuan, Shu-Qiang
    Wang, Yun
    Zou, Xue-Bin
    Chen, Shi
    Li, Shu-Man
    Duan, Jin-Ling
    Zhou, Jie
    Chen, Guo-Ming
    Luo, Tian-Qi
    Zhou, Zhi-Wei
    Li, Yuan-Fang
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [10] Kidney retransplantation after anti-programmed cell death-1 (PD-1)-related allograft rejection
    Lipson, Evan J.
    Naqvi, Fizza F.
    Loss, Manisha J.
    Schollenberger, Megan D.
    Pardoll, Drew M.
    Moore, Jack, Jr.
    Brennan, Daniel C.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 (08) : 2264 - 2268
12345